Advancing Patient Selection in Oncology: Enrichment Strategies and Emerging Diagnostics

Prior to joining the industry, Dr. Brian Barnett, MD was a medical oncologist working in private practice. At Tulane University, he served as an Assistant Professor of Hematology and Medical Oncology, focusing on Regulatory T Cells in academic medicine. Along with Dr. Barnett’s experience in clinical practice, he has accumulated over 20 years of industry experience in translational research, medical monitoring, and regulatory meeting preparations. Dr. Barnett has held various impactful roles throughout his time in the pharmaceutical space, including Chief Medical Officer. At Allucent, Dr. Barnett provides the A-Team with expert guidance on both early- and late-stage drug and cell therapy clinical development.

Justin Devine is a medical doctor, immunologist and pharmacologist (Stellenbosch University). As the co-founder and Chief Innovation Officer at Synexa Life Sciences, his primary focus is designing biomarker strategies to bring real insight to the challenges of clinical development. Justin has a very deep understanding of the role that biomarkers and pharmacogenetics play in understanding the performance of a candidate drug. He is particularly passionate about improving the drug development process by bringing innovative approaches to early phase research, including new ideas in translational medicine, bioinformatics and artificial intelligence. 

Lisa Eli is a Translational Medicine leader with over 20 years of experience integrating biomarkers, diagnostics, and clinical development in Oncology. Dr. Eli most recently served as Vice President of Translational Medicine and Diagnostics at Puma Biotechnology. Dr. Eli holds a PhD in Biochemistry from Stanford University and has a proven track record of driving biomarker strategies and translational insights to support regulatory approvals, NCCN guidelines inclusions, and high-impact publications. She is skilled in building cross-functional alliances, engaging global key opinion leaders (KOLs), and interfacing with regulatory agencies. Her leadership has played a pivotal role in shaping corporate strategy within dynamic, high-growth biotech environments.